Search clinical trials for: Comparator: pioglitazone

Total 2512 results

Daiichi Sankyo Co., Ltd.

Completed

Placebo and Active Comparator Controlled Dose Response Study of Rivoglitazone in Type 2 Diabetes (RAISE)

Type 2 Diabetes

China
Merck Sharp & Dohme LLC

Terminated

Efficacy and Tolerability of MK0533 in Patients With Type 2 Diabetes (0533-005)

Diabetes Mellitus Type 2
Clinical Nutrition Research Center, Illinois Institute...

Completed

Dose-dependent Effect of Grape Seed Extract on Glucose Control in People With Impaired Glucose Tolerance (GSE3)

Impaired Glucose Tolerance

United States
Merck Sharp & Dohme LLC

Completed

Effects of Pioglitazone on Insulin Sensitivity in Healthy Overweight and Obese Males (MK-0000-170)

Healthy | Obesity | Overweight
Daiichi Sankyo, Inc.

Terminated

Randomized, Double-blind, Active-controlled, Study of Rivoglitazone in Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus

United States
Merck Sharp & Dohme LLC

Completed

Sitagliptin and Pioglitazone Mechanism of Action Study in Type 2 Diabetes Mellitus (0431-061)

Type 2 Diabetes Mellitus (T2DM)
Daiichi Sankyo, Inc.

Completed

Placebo and Active Controlled Study of Rivoglitazone in Type 2 Diabetes

Type 2 Diabetes

United States
Merck Sharp & Dohme LLC

Completed

An Investigational Drug Study in Patients With Type 2 Diabetes Mellitus (MK0431-023)

Diabetes Mellitus, Type 2
Daiichi Sankyo, Inc.

Completed

Study of Rivoglitazone in Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus

United States, Germany, Mexico, Romania, Serbia, South Africa, Ukraine, Chile, Peru, Puerto Rico, Austria, Hungary, Slovakia, India, Czechia, Latvia, Argentina, United Kingdom
Merck Sharp & Dohme LLC

Completed

Sulfonylurea Add-on Study in Patients With Type 2 Diabetes Mellitus (0431-035)

Diabetes Mellitus, Type 2
The University of Hong Kong

Completed

Peroxisome Proliferator-Activated Receptor-gamma (PPAR-gamma) Agonist in Diabetic End-Stage Renal Disease Patients

Diabetes | Endstage Renal Disease

Hong Kong
Merck Sharp & Dohme LLC

Completed

A Study to Evaluate the Safety and Efficacy of Sitagliptin 100 mg in Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control (MK-0431-229)

Type 2 Diabetes Mellitus
Merck Sharp & Dohme LLC

Completed

Pioglitazone Add-on Study in Patients With Type 2 Diabetes Mellitus

Diabetes Mellitus, Type 2
The University of Hong Kong
Baxter Healthcare Corporation

Completed

Peroxisome Proliferator-Activated Receptor-Gamma Activation in Peritoneal Dialysis Patients (PPAR)

End-stage Renal Disease

Hong Kong
Metabolic Solutions Development Company

Completed

Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of Mitoglitazone in Type 2 Diabetic Patients

Type 2 Diabetes

United States
Merck Sharp & Dohme LLC

Completed

MK0431 (Sitagliptin) Pioglitazone Add-on Study for Patients With Type 2 Diabetes Mellitus (0431-055)(COMPLETED)

Type 2 Diabetes Mellitus
Dong-A ST Co., Ltd.

Completed

Pharmacokinetic/Pharmacodynamic Drug-drug Interaction of Evogliptin 5 mg and Pioglitazone 30 mg

Type 2 Diabetes

Korea, Republic of
Command Hospital, India

Unknown

A Prospective, Randomized Trial to Compare saroGLitazar With pioglitAZone in Nonalcoholic Fatty livEr Disease (GLAZED)

Fatty Liver

India
Solvay Pharmaceuticals

Completed

A Methodological Study To Evaluate The Effects of Single Oral Doses Of Pioglitazone 45 mg And Rosiglitazone 8 mg On Sodium Balance In Healthy Male Volunteers

Type 2 Diabetes Mellitus

United Kingdom
Merck Sharp & Dohme LLC

Completed

MK0431A vs. Pioglitazone in Patients With Type 2 Diabetes Mellitus (0431A-066)

Type 2 Diabetes Mellitus
University of Campinas, Brazil

Active, not recruiting

Study of Imatinib Discontinuation in Chronic Myeloid Leukemia With Deep Molecular Response (EDI-PIO)

Leukemia, Chronic Myeloid

Brazil
Emory University

Completed

Ketosis Prone Diabetes in African-Americans

Diabetic Ketoacidosis | Ketosis Prone Diabetes | Severe Hyperglycemia

United States
University at Buffalo
Takeda Pharmaceuticals North America, Inc.

Completed

Effect of Pioglitazone on Oxidative Load, Inflammatory End-Points and Vascular Reactivity in Obese Non-Diabetic Patients: A Dose Ranging Study

Inflammation

United States
Assistance Publique - Hôpitaux de Paris
Ministry of Health, France

Not yet recruiting

A Trial to Evaluate the Efficacy of Pioglitazone to Promote Renal Tolerance in ANCA-associated Vasculitis - RENATO Trial (RENATO)

ANCA Associated Vasculitis | Rapidly Progressive Glomerulonephritis | Crescentic Glomerulonephritis
National Cancer Institute (NCI)

Completed

Pioglitazone Hydrochloride in Preventing Head and Neck Cancer in Patients With Oral Leukoplakia

Head and Neck Cancer | Oral Leukoplakia

United States
Merck Sharp & Dohme LLC

Completed

A Study to Evaluate the Efficacy and Safety of Sitagliptin and MK0431A in Comparison to a Commonly Used Medication in Patients With Type 2 Diabetes (0431-068)(COMPLETED)

Type 2 Diabetes Mellitus
Merck Sharp & Dohme LLC

Completed

Initial Combination With Pioglitazone Study (0431-064)

Type 2 Diabetes Mellitus
University of Campinas, Brazil

Recruiting

The Role of Pioglitazone in Vascular Transcriptional Remodeling (PREVALENT)

Myocardial Reperfusion Injury

Brazil
West Virginia University

Recruiting

Pioglitazone Therapy Targeting Fatigue in Breast Cancer

Breast Cancer | Muscle Fatigue

United States
University of Leicester
University Hospitals, Leicester; University Hospital Birmingham

Completed

Trial for People With Established Type 2 Diabetes During Ramadan (T4R)

Type 2 Diabetes

United Kingdom
University of Texas Southwestern Medical Center
National Institutes of Health (NIH)

Completed

Pioglitazone on Pancreatic Steatosis and Bone Health

Obesity | Type 2 Diabetes

United States
University of Texas Southwestern Medical Center

Recruiting

Pathogenesis of Uric Acid Nephrolithiasis: Role of Pioglitazone/Weight Loss

Nephrolithiasis, Uric Acid

United States
Centre Hospitalier Universitaire Dijon

Completed

Influence of Glitazones on the Vasodilatory Effect of High-density Lipoprotein (HDL) Lipoproteins

Type 2 Diabetes

France
Technische Universität Dresden

Completed

Influence of Pioglitazone for Renal Transplant Function in Diabetics

Diabetes Mellitus | Proteinuria | Kidney Transplantation

Germany
GlaxoSmithKline

Completed

Study In Patients With Type 2 Diabetes Who Are Taking Metformin And Sulfonylurea, Metformin And Insulin, Or Insulin

Non-Insulin-Dependent Diabetes Mellitus

United States
Medical University of South Carolina
Takeda Pharmaceuticals North America, Inc.

Completed

Pioglitazone and Serum Asymmetric Dimethylarginine (ADMA) in Patients With Diabetes

Diabetes

United States
National Cancer Institute (NCI)

Terminated

Pioglitazone for Oral Premalignant Lesions

Oral Leukoplakia

United States, Italy, Canada
Takeda
Zinfandel Pharmaceuticals Inc.

Terminated

Biomarker Qualification for Risk of Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease (AD) and Safety and Efficacy Evaluation of Pioglitazone in Delaying Its Onset (TOMMORROW)

Mild Cognitive Impairment Due to Alzheimer's Disease

United States, Germany, Switzerland, United Kingdom, Australia
National Heart, Lung, and Blood Institute (NHLBI)

Withdrawn

Pioglitazone Hydrochloride (Actos(Registered Trademark)) to Treat Asthma

Asthma | Airway Inflammation | Airflow Obstruction | Airway Hyperactivity

United States
Torrent Pharmaceuticals Limited

Completed

Bioequivalence Study of Torrent Pharmaceuticals Ltd's Pioglitazone Hydrochloride Tablets Under Fed Conditions

Healthy

India
Brooke Army Medical Center
The Geneva Foundation

Completed

Pioglitazone on Viral Kinetics, Cytokines and Innate Immunity in Insulin Resistant CHC GT 1 Subjects

Chronic Hepatitis C

United States
Dokkyo Medical University

Completed

Effect of Pioglitazone on Cardiovascular Outcome on Higashi-Saitama Trial in Patients With Type 2 Diabetes

Hypertension | Diabetic Nephropathy | Type 2 Diabetes | Dyslipidemia

Japan
National Taiwan University Hospital

Unknown

Treatment of Coronary Atherosclerosis by Insulin Sensitizers in Insulin-Resistant Patients

Inflammation | Coronary Heart Disease | Coronary Atherosclerosis

Taiwan
Dasman Diabetes Institute
Kuwait University; Ministry of Health, Kuwait; Texas Diabetes Institute

Unknown

Effect of Pioglitazone on T2DM Patients With COVID-19 (PIOQ8)

Covid19 | Type 2 Diabetes

Qatar, Kuwait
Children's Hospital Medical Center, Cincinnati

Completed

Pharmacokinetic and Biomarker Study of Pioglitazone in Adolescents With Severe Sepsis and Septic Shock

Septic Shock | Severe Sepsis

United States
Assistance Publique - Hôpitaux de Paris

Completed

Effect of Pioglitazone Administered to Patients With Friedreich's Ataxia: Proof of Concept (ACTFRIE)

Friedreich's Ataxia

France
National Institute of Diabetes and Digestive and...

Completed

Treating Nonalcoholic Steatohepatitis With Pioglitazone

Hepatitis

United States
Vanderbilt University

Terminated

Metabolic Effects of Thiazolidinediones in Chronic Kidney Disease

Chronic Kidney Disease

United States
Wake Forest University Health Sciences

Completed

Pioglitazone Hydrochloride in Preventing Radiation-Induced Cognitive Dysfunction in Treating Patients With Brain Tumors

Glioblastoma Multiforme | Anaplastic Astrocytoma | Brain Neoplasms, Benign | Brain Neoplasms, Malignant | Malignant Meningioma

United States
The University of Texas Health Science Center at...
Takeda Pharmaceuticals North America, Inc.

Completed

Myocardial Dysfunction in Type 2 Diabetes Mellitus (T2DM)

Type 2 Diabetes | Coronary Heart Disease

Search clinical trials for: Comparator: pioglitazone

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Singapore

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations